- Home
- NDLS vs MRNS Comparison
NDLS vs MRNS Comparison
Compare NDLS & MRNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NDLS
- MRNS
- Stock Information
- Founded
- NDLS 1995
- MRNS 2003
- Country
- NDLS United States
- MRNS United States
- Employees
- NDLS N/A
- MRNS N/A
- Industry
- NDLS Restaurants
- MRNS Biotechnology: Pharmaceutical Preparations
- Sector
- NDLS Consumer Discretionary
- MRNS Health Care
- Exchange
- NDLS Nasdaq
- MRNS Nasdaq
- Market Cap
- NDLS 34.3M
- MRNS 29.9M
- IPO Year
- NDLS 2013
- MRNS 2014
- Fundamental
- Price
- NDLS $0.86
- MRNS $0.54
- Analyst Decision
- NDLS Strong Buy
- MRNS Buy
- Analyst Count
- NDLS 2
- MRNS 12
- Target Price
- NDLS $3.00
- MRNS $4.28
- AVG Volume (30 Days)
- NDLS 338.1K
- MRNS 3.2M
- Earning Date
- NDLS 03-06-2025
- MRNS 03-04-2025
- Dividend Yield
- NDLS N/A
- MRNS N/A
- EPS Growth
- NDLS N/A
- MRNS N/A
- EPS
- NDLS N/A
- MRNS N/A
- Revenue
- NDLS $495,817,000.00
- MRNS $31,466,000.00
- Revenue This Year
- NDLS N/A
- MRNS $14.97
- Revenue Next Year
- NDLS $0.14
- MRNS $57.65
- P/E Ratio
- NDLS N/A
- MRNS N/A
- Revenue Growth
- NDLS N/A
- MRNS 1.63
- 52 Week Low
- NDLS $0.55
- MRNS $0.22
- 52 Week High
- NDLS $2.81
- MRNS $10.50
- Technical
- Relative Strength Index (RSI)
- NDLS 61.95
- MRNS 70.29
- Support Level
- NDLS $0.59
- MRNS $0.54
- Resistance Level
- NDLS $0.75
- MRNS $0.56
- Average True Range (ATR)
- NDLS 0.09
- MRNS 0.02
- MACD
- NDLS 0.02
- MRNS 0.01
- Stochastic Oscillator
- NDLS 96.61
- MRNS 93.71
About NDLS Noodles & Company
Noodles & Co is a restaurant concept offering lunch and dinner within the fast-casual segment of the restaurant industry. The company's menu includes a variety of cooked-to-order dishes, including noodles and pasta, soups, salads and appetizers. The company also provides dining, pick-up and delivery services.
About MRNS Marinus Pharmaceuticals Inc.
Marinus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing innovative therapeutics to treat epilepsy and neuropsychiatric disorders. Marinus manages the business in one segment, which is the identification and development of neuropsychiatric therapeutics. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19-RE.